You are here

  • Home
  • Archive
  • Volume 33, Issue Suppl 4
  • PR069/#709  Prognostic impact of erythropoietin-stimulating agents during front-line chemotherapy in patients with ovarian cancer: a Korean multicenter cohort study

Article Text

Article menu

Download PDFPDF

Featured Posters: Poster Rounds with the Professors
AS11. Ovarian cancer
PR069/#709  Prognostic impact of erythropoietin-stimulating agents during front-line chemotherapy in patients with ovarian cancer: a Korean multicenter cohort study
Free
  1. Seung-Hyuk Shim1,
  2. Eunbi Jang2,
  3. Eun Jung Yang2,
  4. Hee Seung Kim3,
  5. Shin Wha Lee4,
  6. Sung Jong Lee5,
  7. Suk-Joon Chang6,
  8. Myong Cheol Lim7 and
  9. Chel Hun Choi8
  1. 1Konkuk University Hospital, Obstetrics and Gynecology, Seoul, Korea, Republic of
  2. 2Konkuk University School of Medicine, Obstetrics and Gynecology, Seoul, Korea, Republic of
  3. 3Seoul National University College of Medicine, Obstetrics and Gynecology, Seoul, Korea, Republic of
  4. 4Asan Medical Center, Department of Obstetrics and Gynecology, Seoul, Korea, Republic of
  5. 5Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Obstetrics and Gynecology, Seoul, Korea, Republic of
  6. 6Ajou University Medical Center, Obstetrics and Gynecology, Suwon, Korea, Republic of
  7. 7Center for Gynecologic Cancer, National Cancer Center, Department of Obstetrics and Gynecology, Goyang, Korea, Republic of
  8. 8Samsung Medical Center, Department of Obstetrics and Gynecology, Seoul, Korea, Republic of

Abstract

Introduction To evaluate whether erythropoiesis-stimulating agents (ESAs) treatment for chemotherapy-induced anemia (CIA) affect progression-free survival (PFS) in patients who received front-line chemotherapy following surgery for ovarian cancer.

Methods We retrospectively reviewed all consecutive patients who received front-line chemotherapy after surgery during 2013–2019 from seven institutions. Patients were divided according to the use of ESA during front-line chemotherapy. Primary endpoint was PFS. The secondary endpoint included occurrence of thromboembolism. A propensity score matching (PSM) analysis was used to compare survival in matched cohorts.

Results Overall, 2,147 patients (433 for ESA and 1,714 for No-ESA) were identified with median follow-up of 44.0 months. ESA group showed significantly higher proportion of stage III/IV disease (81.8% vs 61.1%; P<0.001) and postoperative gross residual (32.3% vs 21.2%; P<0.001) compared to No-ESA group. In multivariable Cox regression, use of ESA did not affect PFS (adjusted hazard ratio, 1.034; 95% confidence interval [CI], 0.891–1.201; P=0.661). The incidence of thromboembolism was 10.2% in the ESA group and 4.6% in the No-ESA group (adjusted odds ratio, 6.581; 95% CI, 3.261–13.281; P<0.001). When comparing the well-matched cohorts after PSM, PFS did not differ between the ESA (median PFS 38 months, range 0.1–77.2 months) and No-ESA group (median PFS 35 months, range 2.2–81.2 months)(P = 0.13, log rank test).

Conclusion/Implications Use of ESA during front-line chemotherapy did not negatively affect PFS in patients with ovarian cancer after surgery but increased risk of thromboembolism.

https://doi.org/10.1136/ijgc-2023-IGCS.109

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.